ADC Therapeutics SA (ADCT) Tops Q3 EPS by 17c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.19), $0.17 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.43 million versus the consensus estimate of $17.98 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
• Atlas Energy Solutions Inc (AESI) PT Lowered to $20 at Stephens
• TuHURA Biosciences receives U.S. patent for delta opioid receptor technology